tolbutamide has been researched along with nateglinide in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (5.26) | 18.7374 |
| 1990's | 4 (21.05) | 18.2507 |
| 2000's | 7 (36.84) | 29.6817 |
| 2010's | 6 (31.58) | 24.3611 |
| 2020's | 1 (5.26) | 2.80 |
| Authors | Studies |
|---|---|
| Dan, K; Fukuma, M; Kumashiro, I; Nishikawa, M; Sato, Y; Seto, Y; Shinkai, H; Toi, K; Toyoshima, S | 1 |
| Hashimoto, Y; Inui, K; Saito, H; Sawada, K; Terada, T | 1 |
| Hashimoto, Y; Inui, K; Saito, H; Uwai, Y | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Kouznetsova, VL; Nagle, MA; Nigam, SK; Tsigelny, IF | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Nishikawa, M; Sato, Y; Shinkai, H; Sukegawa, E | 1 |
| Akiyoshi, M; Kakei, M; Nakazaki, M; Tanaka, H | 1 |
| Fujitani, S; Okazaki, K; Yada, T | 1 |
| Kikuchi, M; Niki, I; Oka, Y; Sakurada, M; Tsukuda, K | 1 |
| Gonoi, T; Ichikawa, K; Kusama, H; Seino, S; Shibasaki, T; Sunaga, Y; Yano, H | 1 |
| Ashcroft, FM; Carr, RD; Christensen, IT; Hansen, AM; Hansen, JB; Wahl, P | 1 |
| Iida, M; Iwase, M; Nakamura, U; Nohara, S; Sasaki, N; Sonoki, K; Uchizono, Y | 1 |
| Abdelmoneim, AS; Brocks, DR; Hasenbank, SE; Light, PE; Seubert, JM; Simpson, SH | 1 |
| Fatehi, M; Lang, VY; Light, PE | 1 |
| Jannetto, PJ; Langman, LJ | 1 |
2 review(s) available for tolbutamide and nateglinide
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Variations in tissue selectivity amongst insulin secretagogues: a systematic review.
Topics: Animals; ATP-Binding Cassette Transporters; Carbamates; Cardiovascular Diseases; Cricetinae; Cyclohexanes; Diabetes Mellitus, Type 2; Gliclazide; Glipizide; Glyburide; Humans; Hypoglycemic Agents; Ischemic Preconditioning, Myocardial; Isoindoles; Mice; Muscle, Smooth, Vascular; Myocytes, Cardiac; Nateglinide; Phenylalanine; Piperidines; Potassium Channels, Inwardly Rectifying; Rats; Receptors, Drug; Risk Factors; Sulfonylurea Compounds; Sulfonylurea Receptors; Tolbutamide | 2012 |
17 other study(ies) available for tolbutamide and nateglinide
| Article | Year |
|---|---|
N-(cyclohexylcarbonyl)-D-phenylalanines and related compounds. A new class of oral hypoglycemic agents. 2.
Topics: Administration, Oral; Animals; Blood Glucose; Chemical Phenomena; Chemistry; Cyclohexanes; Dogs; Hypoglycemic Agents; Magnetic Resonance Spectroscopy; Male; Mice; Molecular Conformation; Nateglinide; Phenylalanine | 1989 |
Inhibitory effect of novel oral hypoglycemic agent nateglinide (AY4166) on peptide transporters PEPT1 and PEPT2.
Topics: Administration, Oral; Alanine; Animals; Caco-2 Cells; Carrier Proteins; Cyclohexanes; Dipeptides; Humans; Hypoglycemic Agents; Kinetics; Nateglinide; Peptide Transporter 1; Phenylalanine; Rats; Symporters; Threonine | 2000 |
Inhibitory effect of anti-diabetic agents on rat organic anion transporter rOAT1.
Topics: Animals; Anion Transport Proteins; Binding, Competitive; Carbon Radioisotopes; Carrier Proteins; Chlorpropamide; Cyclohexanes; Dose-Response Relationship, Drug; Female; Glyburide; Hypoglycemic Agents; Kinetics; Nateglinide; Oocytes; p-Aminohippuric Acid; Phenylalanine; Rats; RNA, Complementary; Sulfonylurea Compounds; Tolbutamide; Xenopus | 2000 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Elucidation of common pharmacophores from analysis of targeted metabolites transported by the multispecific drug transporter-Organic anion transporter1 (Oat1).
Topics: Animals; Cluster Analysis; Computer Simulation; Databases, Factual; Drug Design; Mice; Mice, Knockout; Organic Anion Transport Protein 1; Pharmaceutical Preparations; ROC Curve | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Possibility of ideal blood glucose control by a new oral hypoglycemic agent, N-[(trans-4-isopropylcyclohexyl)-carbonyl]-D-phenylalanine (A-4166), and its stimulatory effect on insulin secretion in animals.
Topics: Animals; Blood Glucose; Cyclohexanes; Diabetes Mellitus, Experimental; Dogs; Glucose Tolerance Test; Glyburide; Hypoglycemic Agents; Insulin; Insulin Secretion; Male; Mice; Mice, Mutant Strains; Nateglinide; Phenylalanine; Rats; Rats, Inbred Strains; Tolbutamide | 1991 |
A new hypoglycemic agent, A-4166, inhibits ATP-sensitive potassium channels in rat pancreatic beta-cells.
Topics: Adenosine Triphosphate; Animals; Calcium Channels; Cyclohexanes; Dose-Response Relationship, Drug; Electrophysiology; Hydrogen-Ion Concentration; Hypoglycemic Agents; Islets of Langerhans; Male; Membrane Potentials; Nateglinide; Phenylalanine; Potassium Channel Blockers; Potassium Channels; Rats; Rats, Wistar; Tolbutamide | 1995 |
The ability of a new hypoglycaemic agent, A-4166, compared to sulphonylureas, to increase cytosolic Ca2+ in pancreatic beta-cells under metabolic inhibition.
Topics: Animals; Calcium; Cyclohexanes; Cytosol; Electron Transport; Enzyme Inhibitors; Gliclazide; Glucokinase; Glucose; Hypoglycemic Agents; Islets of Langerhans; Mitochondria; Nateglinide; Oxidative Phosphorylation; Phenylalanine; Rats; Rats, Wistar; Sulfonylurea Compounds; Tolbutamide | 1997 |
Insulin secretion from isolated rat islets induced by the novel hypoglycemic agent A-4166, a derivative of D-phenylalanine.
Topics: Animals; ATP-Binding Cassette Transporters; Biological Availability; Calcium; Cell Line; Cyclohexanes; Diazoxide; Epinephrine; Glucose; Glyburide; Hypoglycemic Agents; Insulin; Insulin Secretion; Islets of Langerhans; Male; Nateglinide; Phenylalanine; Potassium Channels; Potassium Channels, Inwardly Rectifying; Protein Binding; Rats; Rats, Sprague-Dawley; Receptors, Drug; Rubidium; Somatostatin; Stereoisomerism; Sulfonylurea Receptors; Tolbutamide | 1998 |
The effects of mitiglinide (KAD-1229), a new anti-diabetic drug, on ATP-sensitive K+ channels and insulin secretion: comparison with the sulfonylureas and nateglinide.
Topics: Animals; ATP-Binding Cassette Transporters; Cell Line; COS Cells; Cyclohexanes; Glyburide; Hypoglycemic Agents; Indoles; Insulin; Isoindoles; Nateglinide; Patch-Clamp Techniques; Phenylalanine; Potassium Channels; Potassium Channels, Inwardly Rectifying; Receptors, Drug; Sulfonylurea Compounds; Sulfonylurea Receptors; Tolbutamide; Transfection | 2001 |
Differential interactions of nateglinide and repaglinide on the human beta-cell sulphonylurea receptor 1.
Topics: ATP-Binding Cassette Transporters; Binding, Competitive; Carbamates; Cell Line; Cyclohexanes; Drug Interactions; Electrophysiology; Humans; Islets of Langerhans; Nateglinide; Phenylalanine; Piperidines; Potassium Channels; Potassium Channels, Inwardly Rectifying; Receptors, Drug; Sulfonylurea Receptors; Tolbutamide | 2002 |
Nateglinide, a non-sulfonylurea rapid insulin secretagogue, increases pancreatic islet blood flow in rats.
Topics: 3-O-Methylglucose; Administration, Oral; Anesthesia; Animals; Blood Glucose; Blood Pressure; Consciousness; Cyclohexanes; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Gastrointestinal Tract; Glucose; Hypoglycemic Agents; Injections, Intravenous; Insulin; Insulin Secretion; Islets of Langerhans; Male; Nateglinide; Nitric Oxide Synthase; omega-N-Methylarginine; Phenylalanine; Rats; Rats, Inbred OLETF; Rats, Sprague-Dawley; Regional Blood Flow; Time Factors; Tolbutamide | 2005 |
Pharmacogenomic analysis of ATP-sensitive potassium channels coexpressing the common type 2 diabetes risk variants E23K and S1369A.
Topics: ATP-Binding Cassette Transporters; Chlorpropamide; Cyclohexanes; Diabetes Mellitus, Type 2; Gene Expression Regulation; Gliclazide; Glyburide; Haplotypes; Homozygote; Humans; Isoindoles; Nateglinide; Patch-Clamp Techniques; Phenylalanine; Polymorphism, Single Nucleotide; Potassium Channels, Inwardly Rectifying; Receptors, Drug; Structure-Activity Relationship; Sulfonylurea Compounds; Sulfonylurea Receptors; Tolbutamide | 2012 |
Analysis of Hypoglycemic Drugs by Liquid Chromatography-Tandem Mass Spectrometry.
Topics: Chlorpropamide; Chromatography, High Pressure Liquid; Chromatography, Liquid; Glipizide; Glyburide; Humans; Hypoglycemic Agents; Nateglinide; Pioglitazone; Rosiglitazone; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Tolazamide; Tolbutamide | 2024 |